Larotinib/Larotinib belongs to which generation of targeted drugs

Larotrectinib (Larotrectinib) is a targeted drug that may also be called histology-independent therapy (HIT), or tumor-agnostic therapy. HITs are a newer treatment method that uses specific genetic changes to treat cancer. Often cancer treatments depend on where they start in the body. From the perspective of drug classification, larotinib belongs to the second generation of targeted therapy drugs.

Larotrectinib is a drug indicated for the treatment of solid cancers with neurotrophic tyrosine receptor kinase (NTRK) gene alterations and is an inhibitor of tropomyosin receptor kinase,TRKA, TRKB and TRKC Agents, the NTRK gene can be fused with other genes to produce TRK fusion proteins, leading to solid tumors in different parts of the body. NTRK fusions are rare cancers but appear in many parts of the body, including soft tissue sarcomas, salivary gland cancers, infantile fibrosarcomas, thyroid cancers, and lung cancers. Tyrosine kinases are proteins that cells use to signal each other to promote growth. They act as chemical messengers. Blocking these signals can help slow or stop cancer growth.

Larotrectinib is also the second cancer to be approved based on a common genetic mutation rather than the site of origin; pembrolizumab was the first. First-generation TRK inhibitors are well tolerated by most patients, and their toxicity is characterized by sporadic non-neoplastic, on-target adverse events. Although many patients achieve durable disease control, advanced NTRK fusion-positive cancers eventually become refractory to TRK inhibition; acquisition of NTRK kinase domain mutations can mediate resistance. Fortunately, some resistance mutations can be overcome by second-generation TRK inhibitors. This treatment modality allows larotrectinib to show good efficacy in the treatment of a variety of solid tumors.